The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

case-study
U.S. Based Independent Biotech Company Finds Success in Syner-G’s Capabilities in Manufacturing for Both Pre-Clinical and Clinical Trials Case Studies
Read More

post
Understanding Large Molecule Manufacturing: From Biologics to Market
Read More

case-study
Successful Partnership Improved Efficiencies and Reduced Overall Spend
Read More

post
Formulation Strategies for Large Molecule Drug Products
Read More
Let's move from science to success.
Let’s Talk